PredxBio

PredxBio is powering next-generation cancer therapeutics with AI-driven spatial biomarkers, which delves into the mechanism of action of drugs and predicts patient outcomes with over 95% accuracy.

5 active paying pharma clients, growing revenue ~$1M. 10+ patents granted, 20+ peer-reviewed journal publications. Strategic partnerships for revenue growth with CROs/channel partners and medical centers. Oversubscribed by $1M and closed conv. note round at $2.8M and Series A1 at $2.1M. Currently raising $2M of Series A-2, participation preferred stock, $1.2M is available.

There are significant challenges in managing cancer patients as available therapies only work for ~20% of the time. Moreover, 90% of the drugs fail to get to the market after 8+ years of development. There is an urgent unmet need for accessible treatment options for cancer patients.

Biology in the tumor holds the key to response to therapy. We analyze pre-treatment tumor biopsies to predict response and resistance to therapy. We are unraveling the heterogenous dynamics and hidden complexities of the tumor microenvironment by harnessing spatial multi-omics data (e.g., proteomics, transcriptomics, histology) and predict patient outcomes with over 90% accuracy. The insights we provide to our clients are already helping them design their clinical trials/pipelines better.

We have a recurring revenue model that includes services, SaaS, and Microdomain Atlas Search model. We are currently generating revenue from biopharma companies via opportunistic service projects in Discovery, Translation and Clinical Trials. For all customers, we have master service agreements (MSA) which allows us to realize the recurring revenue with follow-on projects on multiple ongoing clinical trials.

Innovation Works, Alpha Lab Health